Authors : Pradeepa B V; Arshiyazaib M Gadagkar; Dr. Renuka Jartarghar; Dr. R Krishnaprasad

Volume/Issue : Volume 9 - 2024, Issue 12 - December

Google Scholar : https://tinyurl.com/5ajebnr9

Scribd : https://tinyurl.com/2s3aw9k4

DOI : https://doi.org/10.5281/zenodo.14590797

Abstract : Aim: To investigate the potential efficacy of Topical medication group (0.1% preservative free Sodium Hyaluronate, Warm compression & Lid massage) and Intense Pulse Light (IPL) therapy in treating moderate Meibomian gland dysfunction (MGD).  Methodology: The study included 135 patients with moderate MGD, randomly assigned to either the IPL group (2 sessions one week apart) or the Topical medication group (0.1% preservative-free Sodium Hyaluronate drops 6 times daily, along with warm compresses and lid massages). Baseline assessments of OSDI score, TBUT, and Schirmer I tests were conducted, with follow-ups at 1 week (only for IPL group) and 4 weeks.  Result: Following treatment, the IPL group showed significant improvement in TBUT scores, with OD increasing from 3.90 ± 0.80 sec to 9.34 ± 0.72 sec and OS from 4.00 ± 0.79 sec to 9.63 ± 0.75 sec (p < 0.0001 for both). The Topical group also improved significantly, with OD increasing from 4.01 ± 0.74 sec to 7.41 ± 1.77 sec and OS from 4.22 ± 0.79 sec to 7.60 ± 2.07 sec (p < 0.0001). Schirmer I test scores showed no significant change in the IPL group: OD from 11.32 ± 1.97 mm to 12.03 ± 2.30 mm and OS from 11.63 ± 1.84 mm to 12.35 ± 1.70 mm (p = ns). The Topical group also had no significant changes in OD (11.25 ± 1.96 mm to 11.50 ± 1.83 mm) and OS (11.55 ± 1.77 mm to 11.63 ± 1.72 mm) (p = ns). Both groups had significantly reduced OSDI scores, with the IPL group improving more (29.34 ± 2.28 to 11.39 ± 4.81) than the Topical group (28.68 ± 2.57 to 17.70 ± 6.19; p < 0.0001).  Conclusion: Both treatments improved MGD-related dry eye symptoms, with IPL therapy showing greater clinical benefits in alleviating symptoms, increasing tear film stability, and improving Meibomian gland function in patients with moderate MGD.

Keywords : Meibomian Gland Dysfunction; Dry Eye Disease; Schirmer’s Test; Tear Break Up Time; OSDI Questionnaire; IPL Therapy; Sodium Hyaluronate.

References :

1. Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C. K., ... & Stapleton, F. (2017). TFOS DEWS II definition and classification report. The ocular surface, 15(3), 276-283.
2. Jang JH, Lee K, Nam SH, Kim J, Kim JY, Tchah H, Lee H. Comparison of clinical outcomes between intense pulsed light therapy using two different filters in meibomian gland dysfunction: prospective randomized study. Sci Rep. 2023 Apr 24;13(1):6700. Doi: 10.1038/s41598-023-33526-z. PMID: 37095152; PMCID: PMC10126147.
3. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, Yee R, Yokoi N, Arita R, Dogru M. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2006-49. Doi: 10.1167/iovs.10-6997f. PMID: 21450918; PMCID: PMC3072162.
4. Jiang X, Yuan H, Zhang M, Lv H, Chou Y, Yang J, Li X. The Efficacy and Safety of New-Generation Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction-Related Dry Eye: A Multicenter, Randomized, Patients-Blind, Parallel-Control, Non-Inferiority Clinical Trial. Ophthalmol Ther. 2022 Oct;11(5):1895-1912. Doi: 10.1007/s40123-022-00556-1. Epub 2022 Aug 16. PMID: 35974296; PMCID: PMC9437192.
5. Bzovey B, Ngo W. Eyelid Warming Devices: Safety, Efficacy, and Place in Therapy. Clin Optom (Auckl). 2022 Aug 5;14:133-147. Doi: 10.2147/OPTO.S350186. PMID: 35959466; PMCID: PMC9362510.
6. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investigative Ophthalmology & Visual Science. 2011 Mar;52(4):2050-2064.DOI: 10.1167/iovs.10 6997g. PMID: 21450919; PMCID: PMC3072163.
7. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002 Feb;86(2):181-4. Doi: 10.1136/bjo.86.2.181. PMID: 11815344; PMCID: PMC1771021.
8. Tashbayev B, Yazdani M, Arita R, Fineide F, Utheim TP. Intense pulsed light treatment in meibomian gland dysfunction: A concise review. Ocul Surf. 2020 Oct;18(4):583-594. Doi: 10.1016/j.jtos.2020.06.002. Epub 2020 Jul 3. PMID: 32629039.
9. Cheng SN, Jiang FG, Chen H, Gao H, Huang YK. Intense Pulsed Light Therapy for Patients with Meibomian Gland Dysfunction and Ocular Demodex Infestation. Curr Med Sci. 2019 Oct;39(5):800-809. Doi: 10.1007/s11596-019-2108-1. Epub 2019 Oct 14. PMID: 31612399.
10. Chen C, Chen D, Chou YY, Long Q. Factors influencing the clinical outcomes of intense pulsed light for meibomian gland dysfunction. Medicine (Baltimore). 2021 Dec 10;100(49):e28166. Doi: 10.1097/MD.0000000000028166. PMID: 34889288; PMCID: PMC8663838.
11. Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg. 2015 Jan;33(1):41-6. Doi: 10.1089/pho.2014.3819. PMID: 25594770; PMCID: PMC4298157.
12. Vergés C, Salgado-Borges J, Ribot FM. Prospective evaluation of a new intense pulsed light, thermaeye plus, in the treatment of dry eye disease due to meibomian gland dysfunction. J Optom. 2021 Apr-Jun;14(2):103-113. Doi: 10.1016/j.optom.2020.08.009. Epub 2020 Oct 26. PMID: 33121905; PMCID: PMC8093543.
13. Prabhasawat P, Tesavibul N, Kasetsuwan N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br J Ophthalmol. 2007 Jan;91(1):47-50. Doi: 10.1136/bjo.2006.097691. Epub 2006 Sep 14. PMID: 16973668; PMCID: PMC1857566.
14. Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study. J Ocul Pharmacol Ther. 2015 Jul-Aug;31(6):323-9. Doi: 10.1089/jop.2014.0115. Epub 2015 Jun 19. PMID: 26090941; PMCID: PMC4507088.